Study shows ability of Prostascint to predict prostate cancer deaths:
This article was originally published in Clinica
Executive Summary
In what could boost the profile of Prostascint, eight-year outcomes data from a 341-patient study has found that the imaging agent can predict the likelihood of prostate cancer-related deaths. The study, which was presented at last month's American Urological association, in Anaheim, California, found that prostate cancer-specific deaths were 10 times higher in patients that showed central abdominal uptake (CAU) of the agent, which is indicative of metastatic activity. Manufacturers of the agent, Princeton, New Jersey-based Cytogen, commented that the data "reinforces the value of information obtained from Prostascint scans to assist in selection of appropriate therapy". In January of this year, Prostascint was included in the US National Comprehensive Cancer Network (NCCN) clinical practise guidelines for recurrent prostate cancer.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.